Big Data in Hematology

Improving the treatment of Hematologic Malignancies with Big Data analytics

Big Data have an impact on health and in particular on the development of new drugs and therapies for patients. Blood cancers, or hematologic cancers (e.g. leukemia, lymphoma, and myeloma), affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths. Since many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, which results in limited access for patients to the best healthcare. The HARMONY Alliance aims to use "Big Data and Big Data analytics" to provide information that will help to improve the care of patients with these diseases. Read more about unique public-private partnership, funded through the Innovative Medicines Initiative. The European Hematology Association is one of the 53 HARMONY Partners.

Join the HARMONY Network and subscribe to the newsletter.